Letter to the Editor: Hypotension after Etomidate Use in Sepsis by Andrade, Fabio M.
To the Editor:
I congratulate Kim et al. for their study that tries to clarify
an important issue (1). Etomidate has been used for decades,
and its safety has been hotly debated recently (2-7). Etomi-
date has many qualities as a sedative for intubation: it does
not promote respiratory or cardiovascular depression, and it
does not increase intracranial pressure. It is a good option for
neurological patients and has a predictable dose-response. All
this virtues make it an important alternative for sedation
when a procedure is needed, mainly in acutely ill patients
that frequently are in unstable conditions. Nevertheless, the
drug has been criticized, sometimes in a passionate way (8),
due to its blockade in steroids synthesis. Although it’s unques-
tionable that etomidate promotes adrenal suppression that
is detectable even with single bolus use (9), the relevance of
this laboratorial phenomena is far from elucidated. The clini-
cal impact, if there is one, of this suppression (that can last
24 to 48 hr when the drug is used for intubation), is unknown.
This is the fairest statement that can be made at this moment.
Conceivably, many practitioners reserve the drug to the most
unstable patients, and this fact may introduce a bias in ret-
rospective studies. Only randomized, prospective trials will
give us the answers that are urgently needed.
Etomidate is blamed for adrenal suppression, which can
lately induce hypotension or even refractory shock, if untreat-
ed. Curiously, it induces less immediate post-intubation hy-
potension. This is the etomidate paradox.
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The Author Respond
Dear Sir:
Emergent airway establishment in decompensated shock
patients does not need to be meticulously covered, and one
cannot overlook etomidate’s effectiveness as a RSI promoting
sedative.
There is controversy surrounding whether or not etomidate
has any adverse effect on mortality, however recent evidence
seems to suggest that it can act as a possible risk factor for
adrenal insufficiency in patients with severe sepsis.
Therefore, until there is further evidence to the contrary,
we believe that although the use of etomidate should not be
prohibited, we should consider the risk of adrenal insufficien-
cy, consider preparing steroid replacements.
Also, we totally agree with the opinion that the well-de-
signed randomized controlled study will be mandatory.
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